Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin America: insights from a large multinational cohort.
In this study, we evaluated overall survival (OS) and relapse rates in a multinational cohort, aiming to identify key factors associated with these outcomes. In Ph-positive ALL, upfront dasatinib was associated with improved OS, primarily through lower non-relapse mortality rather than reduced relapse incidence.
In this study, we evaluated overall survival (OS) and relapse rates in a multinational cohort, aiming to identify key factors associated with these outcomes. In Ph-positive ALL, upfront dasatinib was associated with improved OS, primarily through lower non-relapse mortality rather than reduced relapse incidence.
What the study was
- Study design
- Retrospective observational study
- Population
- Human participants; details are provided in the abstract.
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Lancet regional health. Americas
Why it surfaced
Retained as a 8/10 high-priority candidate for Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma); PubMed metadata and abstract were assessed conservatively.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.